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Background: Despite the growing incidence of acute kidney injury (AKI) worldwide, there is little data on the
burden and outcomes of AKI in intensive care unit (ICU) in low resource settings. The present study assessed the
incidence of AKI and its impact on mortality in ICU in Kinshasa (Democratic Republic of Congo).
Methods: In a prospective cohort study, 476 consecutive critically ill patients (mean age 52 years, 57 % male) were
screened for the presence of AKI in seven ICU from January 1st to March 30th, 2015. Serum creatinine was
measured by the enzymatic method (Cobas C111 device®). AKI and its stages (no AKI, AKI 1, AKI 2 and AKI 3) were
defined according to AKIN recommendations. The primary outcome was 28 days mortality. Survival (time-to death)
curves were built using the Kaplan Meier methods. Predictors of mortality were assessed by Cox proportional
hazards regression models. p < 0.05 defined the level of statistical significance.
Results: The cumulative incidence of AKI was 52.7 % with AKI stage 1, 2 and 3 in 23.7 %, 16.2 % and 12.8 % of
patients, respectively. Among patients who developed AKI, 146 died (58 %) vs 62 patients (28 %) in the group
without AKI. Only 6.5 % of the patients with AKI stage 3 benefited from dialysis. Median survival time was 15.0 days
in patients without AKI and 3.0 days, 6.0 days and 8.0 days in patients with AKI stage 3, 2 and 1 (p < 0.001),
respectively. In addition to respiratory distress-induced polypnea (HRa 1.60; 95 % CI: 1.08–2.37; p = 0.018), oxygen
desaturation (HRa 1.53; 95 % CI: 1.13–2.08; p = 0.006) and multi-organic involvement (HRa 1.63; 95 % CI: 1.15–2.30),
AKI emerged as an independent predictor of death (HRa 1.82; 95 % CI: 1.34–2.48; p < 0.001).
Conclusion: More than half of critically ill patients in the present cohort developed AKI which contributed
substantially to short-term mortality, highlighting the need for its prevention, early detection and management as
well as the availability of dialysis in ICU.
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Acute kidney injury (AKI) is an abrupt loss of kidney func-
tion which occurs within a few hours or days. It may lead
to a number of complications like high serum potassium
levels, metabolic acidosis, imbalance in body fluid, uremia
and finally death [1]. The new AKI terminology of acute
renal failure stresses that the disease spectrum extends
from less severe forms of injury to more advanced injury
when acute kidney failure may require dialysis [1].
AKI is especially common in hospitalized patients,
particularly in critically ill patients who need intensive
care. Its incidence is growing worldwide because of the
aging population and associated multiple comorbidities
[2, 3]. The systematic measurement of serum creatinine
and quantification of hourly diuresis favor the compre-
hensive detection of AKI in hospitalized patients.
In Western countries, the frequency of AKI in ICU
has been reported to vary from 5% to 60 % [4, 5]. The
lack of standardization of the definition of AKI until re-
cently can explain the differences between studies. AKI
in ICU is associated with high mortality, longer hospital
stay and greater costs especially in patients requiring
hemodialysis [6]. In sub-Saharan Africa (SSA), the situ-
ation is even more crucial since most ICU are poorly
equipped and staffed [7]. Indeed, AKI is a challenging
problem in low-resource settings because of the high
burden of infectious diseases such as HIV and malaria,
the over the counter availability of potentially nephro-
toxic drugs and medicinal plants, the late presentation
of patients to healthcare services and the lack of
hemodialysis centers which, when present, are not
financially accessible to the vast majority of the popula-
tion [8, 9]. Despite the ever growing incidence of AKI
worldwide, there is little data on the burden and
outcomes of AKI in ICU in low resource settings.
In the Democratic Republic of the Congo (DRC), acute
renal failure, prior to the standardization of AKI defin-
ition, has been reported to be a common finding in
hospitalized patients [9]. We therefore took advantage of
the standardization of AKI definition to generate data
on its burden in ICU. The aim of the present study was
thus to determine the overall incidence and outcomes of
AKI in ICU in Kinshasa/DR Congo.Methods
The study was conducted in seven ICU: University hos-
pital of Kinshasa, Clinique Ngaliema, Centre hospitalierMonkole, Hôpital Biamba Marie Mutombo, Centre
médical de Kinshasa, Hôpital général provincial de référ-
ence de Kinshasa, hôpital de l’amitié sino-congolaise from
January1st to March 30th , 2015. All patients aged ≥20
years, hospitalized during the study period were included
in the study. A survey form was used to collect demo-
graphic information (gender, age), the patient’s medical his-
tory (hypertension, diabetes mellitus, stroke, cancer, heart
failure, chronic kidney disease, last serum creatinine meas-
urement, HIV positivity, cirrhosis, obstructive uropathy,
sickle cell anemia), lifestyle habits (alcohol intake, smoking,
NSAIDs and medicinal plants intake), the cause of ICU ad-
mission, the number of vital organs with dysfunction, per-
ipheral oxygen saturation and diuresis. Comorbidities were
classified according to the International Classification of
Diseases-10 (ICD-10). Serum creatinine was measured
using the enzymatic method (Cobas C111 device®). The
highest value of serum creatinine was used to stage AKI
using the Acute Kidney Injury Network (AKIN) with
different stages of AKI (no AKI, AKI 1, AKI 2 and AKI 3)
[1]. Data related to the outcome of AKI were the duration
of hospitalization, survival (time-to-death), hemodialysis
start or not and the vital status until the 28th day.
Statistical analyses were performed using SPSS 21.0 for
Windows (SPSS Inc., Chicago, IL, USA). Comparisons
between groups were performed using Student’s t test,
Fisher’s exact test, Mann-Whitney test and Chi square
test, as appropriate. Kaplan Meier curves were built for
survival analyses. Cox regression analysis was used to
identify independent predictors of mortality. Association
measures were calculated with 95 % confidence intervals.
P < 0.05 defined the level of statistical significance.
The study protocol was approved by the ethical
committee of the School of public health of the
University of Kinshasa. Written informed consent was
obtained from the study participants. For patients unable
to give consent because of severity of illness, the next of
kin was identified and gave informed consent.Results
General characteristics of patients hospitalized in ICU
The study population consisted of 476 patients, 269 men
and 207 women. Patients with medical conditions
numbered 393 (82.6%) and those with surgical condi-
tions 83 (17.4%). The age of patients was 51.9 ± 17.9
(range 20 to 99) years with a significant difference
between genders (men: 53.4 ± 16.9 years vs women: 49.9 ±
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came from other hospitals while 25.6 % were transferred
from the emergency or other units of the same hospital
because of worsening status.
Overall incidence and causes of AKI
The overall incidence of AKI was 52.7 % with AKI stage
1, 2 and 3 in 23.7 % 16.2 % and 12.8 % of patients, re-
spectively. Table 1 shows that patients with AKI were
taking NSAIDs more frequently and were more likely to
have CKD compared with the group without AKI.
Hypertension and diabetes were the most common co-
morbidities, whatever the group studied (AKI vs no
AKI). Patients who had AKI stage 2 or 3 were older than
patients without AKI or with AKI stage 1.
The causes of AKI are detailed in Table 2. According to
ICD-10, infectious diseases and cardiovascular system dis-
eases tended to be associated with AKI, but without sig-
nificant difference compared to the group without AKI.
Metabolic, genitourinary system and digestive system dis-
eases were more frequent in the group with AKI (Table 2).
Survival estimates and predictors of mortality in critically
ill patients
Among all patients with AKI stage 3, only 4 patients
(6.5 %) underwent hemodialysis. Among patients who
developed AKI, 146 died (58 %) vs 62 patients (28 %)
in the group without AKI. The median survival time
was 15.0 ± 4.7 days in patients without AKI and de-
clined with the severity of AKI being of 3.0 ± 0.5 days,
6.0 ± 1.7 days and 8.0 ± 1.7 days in patients with AKI





Age 50.6 ± 17.2 49.9 ± 17.8
Men 122(54.2) 67(59.3)
K > 5.5 mmol/l














Values are n (%) or means ± SD
Abbreviations: HIV/AIDS Human immunodeficiency virus infection and acquired imm
chronic kidney disease, GCS Glasgow coma scale
aResults not available in all patients in the studyaddition to respiratory distress-induced polypnea (aHR
1.60; 95% CI 1.08–2.37; p =0.018) and oxygen desaturation
(aHR 1.53; 95% CI 1.13–2.08; p = 0.006), AKI emerged
as an independent predictor of death (aHR 1.82; 95%
CI 1.34–2.48; p < 0.001) (Table 3). The involvement of
at least two vital organs or systems (aHR 1.63; 95%
CI 1.15–2.30) conferred a 2-fold increase in the risk
of death. The risk of dying increased significantly
with the severity of AKI (Table 4).
Discussion
This prospective cohort study showed that AKI is com-
mon in critically ill patients admitted to ICU in Kinshasa
(RDC) and is associated with high short-term mortality.
Medical conditions, mainly infectious and cardiovascu-
lar, were the main causes of AKI, with history of CKD
and NSAIDs use as main risk factors. Few patients at
AKI stage 3 had access to hemodialysis and respiratory
distress increased the risk of death.
The incidence of AKI in ICU (52.7 %) observed in the
present study is similar to that reported in the Western
World [3–5, 10–13]. Comparison of our results with
other studies from SSA is very hard since most of them
used non-standardized definitions of AKI [14, 15]. Previ-
ous studies acknowledged that the epidemiology of AKI
in developing countries, characterized mainly by its on-
set at younger age and the high incidence of infectious
diseases differs from that of the western world where
aging and associated degenerative diseases prevail [16, 17].
However, the average age of patients of 51.9 years in the
present study underlines the ongoing demographic transi-






















une deficiency syndrome, NSAIDs non-steroidal anti-inflammatory drugs, CKD
Table 2 Association between diseases groups according to ICD-10 and AKI









Infectious and parasitic 104(46.2) 66(58.4) 36(46.8) 34(55.7) 0.135
Circulatory system 104(46.2) 48(42.5) 29(37.7) 26(42.6) 0.616
Endocrine, nutritional and metabolic 75(33.3) 56(49.6) 28(36.4) 21(34.4) 0.033
Genitourinary system 44(19.6) 33(29.2) 21(27.3) 17(27.9) 0.048
Respiratory system 43(19.1) 23(20.4) 9(11.7) 13(21.3) 0.370
Digestive system 22(9.8) 14(12.4) 11(14.3) 13(21.3) 0.020
Blood, blood forming organs and immune mechanisms 17(7.6) 15(13.3) 10(13.0) 5(8.2) 0.265
Abbreviations: ICD international classification of diseases
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present study. This finding highlights the aging-induced
renal morphological and functional changes that render
this organ more vulnerable to AKI. Early diagnosis and
prevention of AKI in these patients is vital. Patients with
AKI were predominantly males. This finding agrees with
previous data and can be explained by the deleterious ef-
fects of male hormones on the kidneys through acceler-
ated apoptosis. Indeed, experimental studies of the
occlusion of the renal artery demonstrated the protective
role of estradiol against ischemia in female animals [19].
Although less commonly found in the present study, a
history of CKD was a risk factor for AKI. It is known
that AKI associated with critical illness is likely modified
by the presence of CKD [20]. Similarly, the development
of AKI in patients with CKD may modify the natural
history of their illness and accelerate progression
towards end-stage kidney disease [21]. NSAIDs intake
was also significantly associated with AKI. NSAIDs canFig. 1 Survival in patients with AKI versus without AKIcause two different forms of AKI: haemodynamically
mediated (eg, pre-renal injury and/or acute tubular
necrosis) and immune mediated (eg, acute interstitial
nephritis) [22]. NSAIDs reversibly inhibit the production
of renal prostaglandins via the inhibition of cyclooxygen-
ase 1 (COX-1) and COX-2. It is unclear how NSAIDs
induce acute interstitial nephritis. However, it has been
suggested that COX inhibition causes preferential con-
version of arachidonic acid to leukotrienes, which may
then activate helper T cells [22].
The most common etiologies of AKI found were infec-
tions, circulatory system (shock), metabolic and genitouri-
nary diseases. The finding of infections as one of the main
causes of AKI in the present study is consistent with the
results previous reports that have found AKI a challenging
problem in sub-Saharan Africa because of increased
prevalence of malaria, sepsis, diarrheal disease, human im-
munodeficiency virus (HIV) and nephrotoxins [9, 23].
Shock whatever its origin as well as genitourinary diseases
Fig. 2 Survival in patients with AKI stage 1, 2 and 3
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contribution of metabolic causes (largely dominated by
diabetic hyperosmolar and acido-ketosis coma) is of ut-
most importance since it does translate the deleterious
impact on the kidney of the epidemiological transition
characterized by the dual epidemic of infectious and non-
communicable diseases in sub-Saharan Africa [24]. In the
present study, there was few cases of AKI-related to the
use of potential nephrotoxic drugs (NSAIDs) and non-
secured medicinal plants probably because toxicological
investigations were not performed systematically.
Our analysis of a cohort of 476 patients from 7 ICU in
Kinshasa using the AKIN classification showed a significantTable 3 Risk factors and all-cause mortality in critically ill patients
Characteristics n PD Deaths Mortality rate
(per 1000 PD) b
AKI
- no AKI 225 1420 62 43.7
- AKI 251 1451 146 100.6
Systems affected
- <2 202 1066 47 44.1
- ≥2 274 1805 161 89.2
Peripheral oxygene saturation
- ≥90 364 2195 131 59.7
- <90 % 112 676 77 113.9
Polypnea
- <24 cycles/min 158 863 34 39.4
- ≥24 cycles/min 318 2008 174 86.7
Overall 476 2871 208 72.4
Patients contributed a total of 2871 days of follow-up. Overall the mortality rate wa
aFour variables listed in the table were introduced in the Cox model
bPD: patient-daysincrease in the risk for mortality in patients who developed
AKI compared with patients who did not. The increased
risk was found to be proportional to the stage of AKI.
These results are consistent with previous western studies
[25]. The increased mortality rate in AKI 1 and AKI 2 poses
the problem of ICU in SSA. It is about the equipment (res-
pirator), the availability of drugs and training of intensivists
without forgetting the management of late referall patients,
who very often spend too long in small centers or with
traditional practitioners before being transferred to
hospitals [7].
For patients who had AKI 3, only 6.5 were able to access
dialysis. Of the 7 hospitals, only one of them has aHazard ratio
Crude (95%CI) p Adjusted a (95%CI) p
1 1
2.30 (1.71–3.10) <0.001 1.82 (1.34–2.48) <0.001
1 1
2.32 (1.68–3.22) <0.001 1.63 (1.15–2.30) 0.006
1 1
2.22 (1.67–2.95) <0.001 1.53 (1.13–2.08) 0.006
1 1
2.43 (1.68–3.51) <0.001 1.60 (1.08–2.37) 0.018
s 72.4 (95%CI: 62.6–82.3) patients per 1000 patient-days
Table 4 Risk of dying in patients with vs patients without AKI
Stages of AKI n (%) of deaths Risk vs no AKI CI 95 %
no AKI 62 (27.5) - -
AKI 1 53 (46.9) 1.702 1.275–2.272
AKI 2 45 (58.4) 2.120 1.597–2.816
AKI 3 48 (78.7) 2.856 2.227–3.662
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needed dialysis were usually transferred. Considering that
about 50% of patients with AKI 3 had hyperkalemia and/
or metabolic acidosis, it is reasonable to assume that dialy-
sis could reduce the number of deaths in ICU. In Western
countries where the use of hemodialysis is common, mor-
tality rates of AKI in ICU is generally lower [12, 26–28].
However, some retrospective studies applied the RIFLE
classification of AKI to assess outcomes in critically ill
patients, and showed death rates similar to those found in
present study, probably because they selected older
patients who had multiple comorbidities including about
20 to 30% with a history of CKD [28, 29].
Respiratory distress and the decrease in peripheral oxy-
gen saturation were independent predictors of death. These
alterations are pathophysiological consequence of many
medical and surgical conditions. There is an interaction
between respiratory failure and AKI. AKI worsens respira-
tory distress by three mechanisms: systemic inflammatory
response mediated by cytokines, the invasion of the renal
parenchyma by neutrophils and macrophages, the oxidative
stress and the hypervolemia [30]. In turn, respiratory dis-
tress aggravates AKI by two mechanisms: firstly the condi-
tions underlying respiratory distress, may cause water
retention by inappropriately stimulating ADH secretion;
secondly the increase in intrathoracic pressure and result-
ant decreased venous return caused by the mechanical
positive pressure ventilation impair kidney perfusion [30].
Our analysis of a cohort of 476 patients from 7 ICU in
Kinshasa using the AKIN classification showed a signifi-
cant increase in the risk for mortality in patients who
developed AKI compared with patients who did not.
The increased risk was found to be proportional to the
stage of AKI. These results are consistent with previous
western studies [25]. The increased mortality rate in
AKI 1 and AKI 2 poses the problem of ICU in SSA. It is
about the equipment (respirator), the availability of
drugs and training of intensivists without forgetting the
management of late referall patients, who very often
spend too long in small centers or with traditional prac-
titioners before being transferred to hospitals [7].
For patients who had AKI 3, only 6.5 were able to access
dialysis. Of the 7 hospitals, only one of them has a
hemodialysis center. In the other 6 hospitals, patients who
needed dialysis were usually transferred. Considering that
about 50% of patients with AKI 3 had hyperkalemia and/or metabolic acidosis, it is reasonable to assume that dialy-
sis could reduce the number of deaths in ICU. In Western
countries where the use of hemodialysis is common, mor-
tality rates of AKI in ICU is generally lower [12, 26–28].
However, some retrospective studies applied the RIFLE
classification of AKI to assess outcomes in critically ill pa-
tients, and showed death rates similar to those found in
present study, probably because they selected older pa-
tients who had multiple comorbidities including about 20
to 30% with a history of CKD [28, 29].
Respiratory distress and the decrease in peripheral oxy-
gen saturation were independent predictors of death.
These alterations are pathophysiological consequence of
many medical and surgical conditions. There is an inter-
action between respiratory failure and AKI. AKI worsens
respiratory distress by three mechanisms: systemic inflam-
matory response mediated by cytokines, the invasion of the
renal parenchyma by neutrophils and macrophages, the
oxidative stress and the hypervolemia [29]. In turn, respira-
tory distress aggravates AKI by two mechanisms: firstly the
conditions underlying respiratory distress, may cause water
retention by inappropriately stimulating ADH secretion;
secondly the increase in intrathoracic pressure and result-
ant decreased venous return caused by the mechanical
positive pressure ventilation impair kidney perfusion [30].
Limitations
Our study has some limitations that must be considered
in interpreting the results. Indeed, the size of the sample
was not very large, a baseline reference creatinine
(before hospitalization) was not available in many
patients and the determination of serum creatinine was
not calibrated. Furthermore we were unable to assess
the long term survival of patients. The study has the
merit of being a prospective cohort, and benefited from
the participation of nephrologists, intensivists general
practitioners and nurses of ICU who were trained on the
screening of AKI.
Conclusion
AKI is a prevalent problem in ICU and it affects short-
term survival of critically ill patients, multiplying by six
the risk of dying versus patients without AKI, especially
during the first 3 days of hospitalization. Very few pa-
tients can get access to dialysis in the context of SSA.
To combat it, we must focus on prevention and early
treatment. For the most severe cases, it is urgent to pro-
mote dialysis in ICU and make it widely accessible.
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